Pharmacokinetics and safety of glecaprevir and pibrentasvir in HCV-negative subjects with hepatic impairment

Matthew P. Kosloski,Haoyu Wang,David Pugatch,Federico Mensa,Edward Gane,Eric Lawitz,Thomas Marbury,Richard A. Preston,Jens Kort,Wei Liu

Pharmacokinetics and safety of glecaprevir and pibrentasvir in HCV-negative subjects with hepatic impairment

2019

Matthew P. Kosloski
Haoyu Wang
David Pugatch
Federico Mensa
Edward Gane
Eric Lawitz
Thomas Marbury
Richard A. Preston
Jens Kort
Wei Liu

Purpose This study characterized the effects of hepatic impairment on the pharmacokinetics and safety of glecaprevir and pibrentasvir, two direct-acting antivirals used for treatment of chronic HCV infection.

Keywords:

Medicine
Hepatitis C virus
Diabetes mellitus
Anesthesia
Gastroenterology
Hepatic impairment
Glecaprevir
Internal medicine
Pibrentasvir
Pharmacokinetics
dose adjustment
Adverse effect

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations